Frontiers in Drug Design and Discovery is a book series devoted to publishing the latest and the most important advances in drug design and discovery. Eminent scientists have contributed chapters focused on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. This book series should prove to be of interest to all pharmaceutical scientists who are involved in research in drug design and discovery and who wish to keep abreast of rapid and important developments in the field.
Volume 11 of this series brings together reviews covering immunotherapy of sepsis, new antimalarials, and the medicinal use of onions for respiratory diseases, among other topics.
Pharmaceutical scientists, biochemists, researchers in medicine and public health projects
Volume 11 of this series brings together reviews covering immunotherapy of sepsis, new antimalarials, and the medicinal use of onions for respiratory diseases, among other topics.
Topics included in this volume are:
- Heme-oxygenase and autophagy connected as a cytoprotective mechanism: potential therapeutic target
- Development of recombinant therapeutic proteins in animal cells: Challenges and solutions
- Artemisinin Analogues as a Novel Class of Antimalarial Agents: Recent Developments, Current Scenario and Future Perspectives
- The effects of Allium cepa and their derivatives on respiratory diseases and the possible mechanisms of these effects
- Immunotherapy of Sepsis
Audience:
Pharmaceutical scientists, biochemists, researchers in medicine and public health projects
Table of Contents
PREFACELIST OF CONTRIBUTORS
CHAPTER 1 HEME-OXYGENASE AND AUTOPHAGY CONNECTED AS A CYTOPROTECTIVE MECHANISM: POTENTIAL THERAPEUTIC TARGET
- Luiz Ricardo C. Vasconcellos, Rafael Cardoso Maciel Costa Silva and Leonardo H. Travassos
HEME-OXYGENASE
AUTOPHAGY
- Autophagosome Biogenesis
- Autophagosome Maturation
- Selective Autophagy
- HO Products Promoting Autophagy
- CO as a Prototype Autophagy Inducer
- Iron as an Autophagy Inducer
- Biliverdin/bilirubin and Autophagy
CONCLUSION
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ACKNOWLEDGMENTS
LIST OF ABBREVIATIONS
REFERENCES
CHAPTER 2 DEVELOPMENT OF RECOMBINANT THERAPEUTIC PROTEINS IN ANIMAL CELLS: CHALLENGES AND SOLUTIONS
- Eduardo F. Mufarrege, Lucía Carolina Peña and Marianela Masin
INTRODUCTION
CHALLENGES IN THE PRODUCTION OF THERAPEUTIC PROTEINS IN ANIMAL CELLS
TECHNOLOGICAL STRATEGIES FOR INCREASED PROTEIN YIELD IN ANIMAL CELLS
- Gene Sequence Engineering
- Use of Strong Promoter Sequences
- Transcriptional Regulatory E Post-Transcriptional Gene Regulationlements
- Strategies for Post-Transcriptional Gene Regulation
- Cell Engineering
- Protein Transport
- Stability - Apoptosis
- Protein Post-Translational Modifications (PTM)
- Overview of Immunologic Tolerance Mechanisms
- Immune Responses Against Biologics
- Immunogenicity Events in the Clinic
- Strategies for Predicting Therapeutic Protein Immunogenicity
- In Silico Algorithms
- In Vitro Analysis
- Lymphatic Micro-Organoids
- In Vivo Assays
- Clinical Trials
- Alternatives for Mitigating Therapeutic Protein Immunogenicity
- Immune Modulator Agents
- Protein Deimmunization
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
CHAPTER 3 ARTEMISININ ANALOGUES AS A NOVEL CLASS OF ANTIMALARIAL AGENTS: RECENT DEVELOPMENTS, CURRENT SCENARIO AND FUTURE PERSPECTIVES
- Mohit K. Tiwari and Sandeep Chaudhary
INTRODUCTION
- Life Cycle of Malarial Parasite
- Classification of Antimalarial Drugs
- Blood Schizontocides
- Tissue Schizontocides (Causal Prophylaxis)
- Tissue Schizontocides (Radical cure)
- Gametocytocides (Transmission blocking treatment)
- Sporontocides
- Pre-second World War Era: Historical Outlook of Classical N-containing Medications
- Load of Drug Resistance
- Quinolones Resistance Against Plasmodium falciparum
- Quinolones Resistance Against Plasmodium vivax
- Artemisinins Resistance Against Plasmodium Falciparum
- Rediscovery of ‘Qing-hao’
- Mechanism of Action
DEVELOPMENT OF SEMISYNTHETIC ARTEMISININ ANALOGS
- First Generation of Artemisinins
- Pharmacophore for Antimalarial Activity
- Second Generation of Artemisinins
- C10-O Substituted Etheral/Ester DHA Analogues
- C10-C Substituted Carba and Deoxocarba Analogues
- C16-C Substituted Artemisinin Analogues
- C10-N Based Amino Artemisinin Analogues
- Azaartemisinin Analogues
- Artemisinin-Based Hybrids
- C10-O/C10-C ART Dimers
ACRONYMS AND ABBREVIATIONS
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
- MH. Boskabady, N. Marefati, F. Kianian, A. Memarzia, S. Behrouz1 and M. Boskabady
INTRODUCTION
METHODS
RESULTS
- Onion Compounds and their Biologicals Effects
- The Relaxant Effects of A. Cepa and its Derivatives
- Relaxant Effects of A. Cepa on Tracheal Smooth Muscle
- Relaxant Effects of Derivatives from A. Cepa on Tracheal Smooth Muscle
- Preventive Effects of A. Cepa and its Derivatives on Respiratory Disorders
- Preventive Effects of A. Cepa on Respiratory Disorders
- Preventive Effects of Derivatives from A. Cepa on Respiratory Disorders
- The Effects of A. Cepa and its Derivatives on Lung Infections
- The Effects of A. Cepa on Lung Infections, Animal Studies
- The Effects of A. Cepa on Lung Infections, Clinical Studies
- The Effects of Derivatives from A. Cepa on Lung Infections, Animal Studies
- The Effects of Derivatives from A. Cepa on Lung Infections, Clinical Studies
- The Effects of A. Cepa and its Derivatives on Lung Cancer
- The Effects of A. Cepa on Lung Cancer
- The Effects of Derivatives from A. Cepa on Lung Cancer
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ACKNOWLEDGMENTS
REFERENCES
CHAPTER 5 IMMUNOTHERAPY OF SEPSIS
- Sanam Dolati and Hassan Soleimanpour
INTRODUCTION
EPIDEMIOLOGY OF SEPSIS
ETIOLOGY OF SEPSIS
DIAGNOSIS
MATERNAL SEPSIS
NEONATAL SEPSIS
PATHOGENESIS OF SEPSIS
- Inflammation
- Immunosuppression
- Microvascular Damage and Coagulopathy
- Multiple-Organ Dysfunction
- Novel Treatment Modalities in Sepsis
- Antithrombotic Agents
- Antioxidants
- Endotoxin Antagonists
- Nanomedicine for Sepsis Treatment
- Immunotherapy
- Immunomodulatory Agents
- Intravenous Immunoglobulin (IVIG)
- Antibodies Against Inhibitory Immune Checkpoints
- Mesenchymal stem cells (MSCs)
- Autophagy
CONCLUSION
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
- Cellular Immunotherapy
- Myeloid-Derived Suppressor Cells
Author
- Atta-ur-Rahman - Editor
- M. Iqbal Choudhary - Editor
